Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Launched by SANOFI · Jun 8, 2010

Keywords

ClinConnect Summary

The study consists of:

* a screening phase (maximum length of 21-day).
* a treatment phase with 21-day study treatment cycles. Cycle lengths may be extended up to maximum of 12 additional days in case of unresolved toxicity.

Patients continue to receive treatment until they experience, unacceptable toxicities/AEs, disease progression ,withdraw their consent, or the investigator decides to discontinue the patient, or study cut-off, whichever comes first.

* a 30-day follow-up visit after the last dose of study medication.

The cut off date is when the last patient treated has completed cyc...

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients with a diagnosis of advanced, measurable or non-measurable, non-hematological cancer who have varying degrees of hepatic impairment. The cancer must be one that is either refractory to standard therapy or for which no standard therapy exists.
• Exclusion criteria:
• • Eastern Cooperative Oncology Group (ECOG) performance status (PS) \>2
• • Life expectancy \<3 months
• • Need for a major surgical procedure or radiation therapy during the study
• • Evidence of another active malignancy
• • Prior chemotherapy, other investigational drug, biological therapy, targeted non-cytotoxic therapy and radiotherapy within 3 weeks prior to registration
• • Patients with known history of Gilbert's syndrome
• • Prior treatment with Cabazitaxel and a history of severe (Grade ≥3) hypersensitivity to taxanes, polysorbate-80, or to compounds with similar chemical structures
• • Prior history of bone marrow transplant
• • Any treatment known to induce CYP isoenzymes or to inhibit CYP3A4 activities within 2 weeks before or during the test period of the pharmacokinetic sampling. Moderate inhibitors within one week prior and during the pharmacokinetic sampling.
• • Any contra-indications to midazolam, according to the applicable labeling.
• • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.